Literature DB >> 1987845

Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.

J L Cameron1, D W Crist, J V Sitzmann, R H Hruban, J K Boitnott, A J Seidler, J Coleman.   

Abstract

Eighty-nine patients with carcinoma of the head of the pancreas underwent pancreaticoduodenectomies. The actuarial 5-year survival for all 89 patients was 19%, with a median survival of 11.9 months. The 81 hospital survivors were analyzed in an effort to determine factors influencing long-term survival. Negative lymph nodes and the absence of blood vessel invasion both favored long-term survival. The strongest predictive factor was negative lymph node status with a median survival of 55.8 months, compared with 11 months with lymph nodes involved with tumor (p less than 0.05). Blood transfusions were also predictive, with patients receiving two or fewer units having a median survival of 24.7 months, compared with 10.2 months for those receiving three or more units (p less than 0.05). The most important determinant of long-term survival after pancreaticoduodenectomy for pancreatic cancer is biology of the tumor (lymph node status, blood vessel invasion). However, performance of the resection (units of blood transfused) also appears to be an important factor influencing survival.

Entities:  

Mesh:

Year:  1991        PMID: 1987845     DOI: 10.1016/0002-9610(91)90371-j

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  116 in total

1.  Periampullary adenocarcinoma: analysis of 5-year survivors.

Authors:  B Gudjonsson
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

Review 2.  Recent advances in the surgical treatment of pancreatic cancer.

Authors:  A Shankar; R C Russell
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 3.  Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer.

Authors:  D Birk; H G Beger
Journal:  Curr Gastroenterol Rep       Date:  2001-04

4.  Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas.

Authors:  W Meyer; C Jurowich; M Reichel; B Steinhäuser; P H Wünsch; C Gebhardt
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

5.  Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent.

Authors:  Skye C Mayo; Hari Nathan; John L Cameron; Kelly Olino; Barish H Edil; Joseph M Herman; Kenzo Hirose; Richard D Schulick; Michael A Choti; Christopher L Wolfgang; Timothy M Pawlik
Journal:  Cancer       Date:  2011-09-20       Impact factor: 6.860

Review 6.  Perineural invasion and associated pain in pancreatic cancer.

Authors:  Aditi A Bapat; Galen Hostetter; Daniel D Von Hoff; Haiyong Han
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

7.  Factors influencing survival in patients undergoing palliative bypass for pancreatic adenocarcinoma.

Authors:  Phillip J Gray; Jingya Wang; Timothy M Pawlik; Barish H Edil; Richard Schulick; Ralph H Hruban; Harry Dao; John Cameron; Christopher Wolfgang; Joseph M Herman
Journal:  J Surg Oncol       Date:  2012-02-03       Impact factor: 3.454

8.  Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.

Authors:  Deyali Chatterjee; Asif Rashid; Hua Wang; Matthew H Katz; Robert A Wolff; Gauri R Varadhachary; Jeffrey E Lee; Peter W Pisters; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

Review 9.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

10.  Large retroperitoneal paraganglioma concurrent with periampullary adenocarcinoma.

Authors:  Seyed Mohammadreza Hakimian; Azar Naimi; Seyed Mohammadhasan Emami; Golnar Rozatii; Vahid Goharian
Journal:  J Res Med Sci       Date:  2013-12       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.